Table 1.
Clinical characteristics of the study cohort.
| Normal | Tumor | P value | |
|---|---|---|---|
| (N = 44) | (N = 497) | ||
| Vital status: Dead | 70% (31) | 33% (165) | <0.001 |
| Age at diagnosis | 64 (54 to 68) | 61 (53 to 69) | 0.377 |
| Gender: Male | 68% (30) | 72% (360) | 0.547 |
| Race: Black or African American (AA) | 5% (2) | 9% (45) | 0.866 |
| American Indian or Alaskan Native (AI) | 0% (0) | 0% (2) | |
| Asian (As) | 2% (1) | 2% (10) | |
| White (W) | 91% (40) | 86% (427) | |
| Not Reported (NR) | 2% (1) | 3% (13) | |
| Ethnicity: Hispanic or Latino (HLA) | 7% (3) | 5% (25) | 0.876 |
| Not Hispanic or Latino (NHLA) | 86% (38) | 88% (438) | |
| Not Reported (NR) | 7% (3) | 7% (34) | |
| Alcohol history documented: NO | 43% (19) | 32% (159) | 0.097 |
| YES | 52% (23) | 66% (330) | |
| Not Reported (NR) | 5% (2) | 2% (8) | |
| Tobacco smoking history: 1 | 26% (11) | 24% (118) | 0.656 |
| 2 | 26% (11) | 34% (165) | |
| 3 | 21% (9) | 14% (67) | |
| 4 | 28% (12) | 27% (132) | |
| 5 | 0% (0) | 0% (2) | |
| Anatomic Neoplasm Subdivision: Alveolar_Ridge | 0% (0) | 4% (18) | 0.057 |
| Base_of_tongue | 5% (2) | 5% (23) | |
| Buccal_Mucosa | 0% (0) | 4% (20) | |
| Floor_of_mouth | 7% (3) | 12% (59) | |
| Hard_Palate | 0% (0) | 1% (6) | |
| Hypopharynx | 0% (0) | 2% (9) | |
| Larynx | 27% (12) | 23% (112) | |
| Lip | 0% (0) | 1% (3) | |
| Oral_Cavity | 32% (14) | 14% (70) | |
| Oral_Tongue | 30% (13) | 25% (126) | |
| Oropharynx | 0% (0) | 2% (9) | |
| Tonsil | 0% (0) | 8% (42) | |
| Stage T: 0 | 100% (44) | 0% (0) | <0.001 |
| 1 | 0% (0) | 7% (35) | |
| 2 | 0% (0) | 29% (144) | |
| 3 | 0% (0) | 28% (138) | |
| 4 | 0% (0) | 36% (180) | |
| Stage N: 0 | 100% (44) | 48% (241) | <0.001 |
| 1 | 0% (0) | 17% (84) | |
| 2 | 0% (0) | 33% (164) | |
| 3 | 0% (0) | 2% (8) | |
| Stage M | 0% (0) | 1% (6) | 0.459 |
| Stage event pathologic stage: NR (Not Reported) | 0% (0) | 15% (73) | N/A |
| Stage_I | 0% (0) | 5% (24) | |
| Stage_II | 0% (0) | 14% (69) | |
| Stage_III | 0% (0) | 14% (72) | |
| Stage_IVA | 0% (0) | 49% (246) | |
| Stage_IVB | 0% (0) | 2% (12) | |
| Stage_IVC | 0% (0) | 0% (1) | |
| Tissue source site: 4P | 0% (0) | 0% (1) | <0.001 |
| BA | 0% (0) | 7% (34) | |
| BB | 0% (0) | 4% (19) | |
| C9 | 0% (0) | 0% (2) | |
| CN | 0% (0) | 14% (72) | |
| CQ | 0% (0) | 7% (34) | |
| CR | 0% (0) | 11% (53) | |
| CV | 86% (38) | 27% (134) | |
| CX | 0% (0) | 1% (4) | |
| D6 | 0% (0) | 4% (20) | |
| DQ | 0% (0) | 3% (14) | |
| F7 | 0% (0) | 1% (6) | |
| H7 | 5% (2) | 1% (6) | |
| HD | 7% (3) | 2% (12) | |
| HL | 0% (0) | 0% (1) | |
| IQ | 0% (0) | 2% (12) | |
| KU | 0% (0) | 1% (4) | |
| MT | 0% (0) | 1% (6) | |
| MZ | 0% (0) | 1% (3) | |
| P3 | 0% (0) | 3% (14) | |
| QK | 0% (0) | 3% (17) | |
| RS | 0% (0) | 0% (2) | |
| T2 | 0% (0) | 1% (4) | |
| T3 | 0% (0) | 0% (2) | |
| TN | 0% (0) | 0% (1) | |
| UF | 0% (0) | 4% (18) | |
| UP | 0% (0) | 0% (1) | |
| WA | 2% (1) | 0% (1) |
Bold fonts highlight P values lower than 0.1, which were considered indicative of baseline imbalance between the normal and tumor samples.